| 方梓儒,蒋锐沅,朱佳裕,等.2023 ASCO肿瘤浸润淋巴细胞预测乳腺癌疗效的研究进展[J].肿瘤学杂志,2023,29(9):739-743. |
| 2023 ASCO肿瘤浸润淋巴细胞预测乳腺癌疗效的研究进展 |
| Studies on Tumor-Infiltrating Lymphocytes in Predicting the Efficacy of Breast Cancer Treatment in ASCO 2023 |
| 投稿时间：2023-07-25 |
| DOI：10.11735/j.issn.1671-170X.2023.09.B003 |
|
 |
| 中文关键词: 肿瘤浸润淋巴细胞 乳腺癌 肿瘤微环境 预后 ASCO |
| 英文关键词:tumor infiltrating lymphocyte breast cancer tumor microenvironment prognosis ASCO |
| 基金项目:浙江省重点研发计划（国际合作技术研发与示范推广项目）（2020CO4012）；国家重点研发计划“政府间国际科技创新合作”重点专项立项项目（2019YFE0196500） |
|
| 摘要点击次数: 387 |
| 全文下载次数: 332 |
| 中文摘要: |
| 摘 要：在2023年美国临床肿瘤学会（ASCO）大会上，肿瘤浸润淋巴细胞（tumor infiltrating lymphocytes，TILs)成为关注的焦点，大会主旨报告中的A505、A507、A508分别报道TILs在Luminal型、三阴性及HER2阳性乳腺癌的抗肿瘤治疗疗效方面具有较好的预测作用。壁报会议中也有多项研究围绕TILs在不同亚型乳腺癌中的作用展开探索。研究报告提示TILs与乳腺癌进展转移相关，TILs可作为乳腺癌临床生物标志物。全文就2023 ASCO 关于TILs在乳腺癌疗效预测作用的最新进展进行报道。 |
| 英文摘要: |
| Abstract： Tumor infiltrating lymphocytes(TILs) are in the spotlight at the 2023 American Society of Clinical Oncology Congress (ASCO). The oral presentations A505， A507 and A508 in the conference reported that TILs had a good predictive value for therapeutic efficacy of Luminal， triple-negative and HER2-positive breast cancer. In addition， a number of studies shown in the poster session focused on the role of TILs in different subtypes of breast cancer. These studies highlighted the association of TILs with metastatic breast cancer progression and its potential application as a biomarker for treatment efficacy of breast cancer. This review summarizes the update progress of TILs in predicting curative effects of breast cancer presented in ASCO 2023. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |